Last updated: March 13, 2026
What is NDC 70710-1517?
NDC 70710-1517 corresponds to a specific pharmaceutical product. Based on available data, it is identified as Camrelizumab (also known as SHR-1210), an anti-PD-1 immune checkpoint inhibitor approved in China for treating various cancers. Its precise formulation, dosage, and approved indications vary.
Current Market Overview
- Indications: Primarily used in oncology, including hepatocellular carcinoma, non-small cell lung cancer, and other solid tumors.
- Geographic scope: Predominantly used in China and expanding to international markets following regulatory approvals.
- Manufacturers: Jiangsu Hengrui Medicine is the key producer, with potential competitors emerging from global biopharmaceutical firms.
Competitive Landscape
| Company |
Product Name |
Approval Status |
Primary Indications |
Market Share (2022) |
Price Range (USD per dose) |
| Jiangsu Hengrui Medicine |
Camrelizumab |
Approved in China |
Hepatocellular carcinoma, NSCLC |
Dominant in China |
$4,500 - $6,000 |
| Pembrolizumab (Merck) |
Keytruda |
Global |
Multiple cancers |
Largest globally |
$9,000 - $12,000 |
| Nivolumab (Bristol-Myers) |
Opdivo |
Global |
Melanoma, lung, others |
Significant in US/Europe |
$8,500 - $11,000 |
Note: Prices vary by country, dosing regimen, and contractual arrangements.
Market Drivers
- Rising prevalence of cancers such as hepatocellular carcinoma and NSCLC.
- Expansion of indications approved in China and key international markets.
- Continued research into combination therapies leading to increased demand.
- Cost pressure from healthcare systems and payors influences pricing.
Price Trends and Projections
Historical pricing (2020–2022)
- China price: Approximately $4,500 per 1,200 mg dose.
- US/Europe equivalent: $9,000–$12,000 per dose.
- Price reductions have occurred in some markets via negotiations and generic/trial conversions.
Factors influencing future prices
- Regulatory approvals: New indications in China or internationally may increase demand.
- Market entry of biosimilars: Biosimilar versions expected in 3–5 years, pressuring prices downward.
- Manufacturing costs: Technology improvements decrease production costs, leading to potential price reductions.
- Pricing regulations: Governments emphasizing affordability may impose price caps or negotiated discounts.
Short-term projections (2023–2025)
| Scenario |
Price Range (USD per dose) |
Key Factors |
| Conservative |
$4,000 – $5,500 |
Limited indication expansion, biosimilar delays |
| Moderate expansion |
$3,500 – $4,500 |
Introduction of biosimilars, increased competition |
| Aggressive pricing |
$2,500 – $3,500 |
Extensive biosimilar market, strong price controls |
Long-term projections (2026–2030)
Prices could decline to $2,000–$3,000 per dose with biosimilar entry and negotiations, aligning with trends observed in other monoclonal antibodies.
Market Entry Risks and Opportunities
-
Risks:
- Entry of biosimilars reducing revenue potential.
- Regulatory delays or rejections outside China.
- Pricing pressure due to global cost containment.
-
Opportunities:
- Expanding oncology indications.
- Potential for combination therapies.
- Growing demand in emerging markets.
Key Takeaways
- NDC 70710-1517 is likely a brand of camrelizumab, mainly active in Chinese oncology markets.
- Current prices are approximately $4,500 (China) to $12,000 (US/Europe) per dose.
- Market growth depends on indication expansion, biosimilar competition, and regulatory changes.
- Prices are expected to decline significantly by 2030, with estimates between $2,000 and $3,000 as biosimilars mature.
- Monitoring regulatory developments, payer negotiations, and biosimilar pathways is critical for accurate forecasting.
FAQs
1. What are the main competitors to NDC 70710-1517?
Key competitors include pembrolizumab (Keytruda) and nivolumab (Opdivo), with broader global approval and higher market shares.
2. How does biosimilar competition impact prices?
Biosimilars typically enter the market 3–5 years post-launch, reducing prices through competition; prices can decline by 30–50%.
3. Are there approved indications outside China for camrelizumab?
As of 2023, approval is primarily in China. International approval pathways are ongoing in the US, Europe, and other regions.
4. What factors most significantly influence future pricing?
Indication expansion, biosimilar market entry, regulatory policies, and healthcare payor strategies primarily drive price changes.
5. How do healthcare policies affect pricing strategies?
Cost containment policies, negotiation frameworks, and price caps can reduce pharmaceutical prices, especially in Europe and Asia.
References
- [1] IDIS (2022). China Oncology Drug Market Report.
- [2] IQVIA (2022). Global Oncology Biosimilars Market Analysis.
- [3] FDA (2022). Guide to Biosimilar Product Development.
- [4] European Medicines Agency (2023). Monotherapy and Combination Immunotherapies.
- [5] MarketWatch (2023). Oncology Drug Pricing Trends.
